Veronique Lecault's most recent trade in AbCellera Biologics Inc was a trade of 539,265 Share option (right to buy) done . Disclosure was reported to the exchange on Jan. 1, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| AbCellera Biologics Inc | Veronique Lecault | Director, Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2026 | 539,265 | 5,201,069 | - | - | Share option (right to buy) | |
| AbCellera Biologics Inc | Veronique Lecault | Director, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2025 | 832,033 | 4,661,804 | - | - | Share option (right to buy) | |
| AbCellera Biologics Inc | Veronique Lecault | Director, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.19 per share. | 21 Jun 2024 | 83,334 | 2,123,456 | - | 0.2 | 15,667 | Common Shares |
| AbCellera Biologics Inc | Veronique Lecault | Director, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jun 2024 | 83,334 | 3,829,771 | - | - | Share option (right to buy) | |
| AbCellera Biologics Inc | Lecault Veronique | Director, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2024 | 770,416 | 3,913,105 | - | - | Share option (right to buy) | |
| AbCellera Biologics Inc | Veronique Lecault | Director, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.19 per share. | 05 May 2023 | 250,000 | 2,020,122 | - | 0.2 | 47,500 | Common Shares |
| AbCellera Biologics Inc | Veronique Lecault | Director, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 May 2023 | 250,000 | 3,142,689 | - | - | Share option (right to buy) | |
| AbCellera Biologics Inc | Veronique Lecault | Director, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2022 | 462,535 | 3,392,689 | - | - | Share Options (right to buy) | |
| AbCellera Biologics Inc | Veronique Lecault | Director, Chief Operating Officer | Purchase of securities on an exchange or from another person at price $ 6.34 per share. | 16 May 2022 | 200,000 | 1,770,122 | - | 6.3 | 1,267,780 | Common Shares |
| AbCellera Biologics Inc | Veronique Lecault | Director, Chief Operating Officer | Purchase of securities on an exchange or from another person at price $ 8.66 per share. | 28 Feb 2022 | 230,789 | 1,570,122 | - | 8.7 | 1,998,633 | Common Shares |
| AbCellera Biologics Inc | Veronique Lecault | Director, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.19 per share. | 08 Dec 2021 | 250,000 | 1,589,333 | - | 0.2 | 47,500 | Common Shares |
| AbCellera Biologics Inc | Veronique Lecault | Director, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Dec 2021 | 250,000 | 2,524,134 | - | - | Share Option (right to buy) | |
| AbCellera Biologics Inc | Veronique Lecault | Director, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Dec 2021 | 406,020 | 2,930,154 | - | - | Share Option | |
| AbCellera Biologics Inc | Veronique Lecault | Director, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Nov 2021 | 83,333 | 2,774,134 | - | - | Share Option (right to buy) | |
| AbCellera Biologics Inc | Veronique Lecault | Director, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.19 per share. | 30 Nov 2021 | 83,333 | 1,422,666 | - | 0.2 | 15,833 | Common Shares |